1. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real‐world experience study. Issue 11 (3rd July 2018) Authors: Flisiak, R.; Janczewska, E.; Łucejko, M.; Karpińska, E.; Zarębska‐Michaluk, D.; Nazzal, K.; Bolewska, B.; Białkowska, J.; Berak, H.; Fleischer‐Stępniewska, K.; Tomasiewicz, K.; Karwowska, K.; Simon, K.; Piekarska, A.; Tronina, O.; Tuchendler, E.; Garlicki, A. Journal: Journal of viral hepatitis Issue: Volume 25:Issue 11(2018) Page Start: 1298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters. (April 2019) Authors: Parczewski, M.; Kordek, J.; Janczewska, E.; Pisula, A.; Łojewski, W.; Socha, Ł.; Wawrzynowicz-Syczewska, M.; Bociąga-Jasik, M.; Szymczak, A.; Cielniak, I.; Siwak, E.; Mularska, E.; Aksak-Wąs, B.; Urbańska, A.; Lübke, N. Journal: Clinical microbiology and infection Issue: Volume 25:Number 4(2019) Page Start: 513.e1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: Epi-Ter2 study. Issue 6 (2nd June 2020) Authors: Piekarska, A.; Jabłonowska, E.; Garlicki, A.; Sitko, M.; Mazur, W.; Jaroszewicz, J.; Czauz-Andrzejuk, A.; Buczyńska, I.; Simon, K.; Lorenc, B.; Dybowska, D.; Halota, W.; Pawłowska, M.; Dobracka, B.; Berak, H.; Horban, A.; Tudrujek-Zdunek, M.; Tomasiewicz, K.; Janczewska, E.; Socha, Ł. Journal: AIDS care Issue: Volume 32:Issue 6(2020) Page Start: 762 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Issue 9 (9th September 2016) Authors: Flisiak, R.; Janczewska, E.; Wawrzynowicz‐Syczewska, M.; Jaroszewicz, J.; Zarębska‐Michaluk, D.; Nazzal, K.; Bolewska, B.; Bialkowska, J.; Berak, H.; Fleischer‐Stępniewska, K.; Tomasiewicz, K.; Karwowska, K.; Rostkowska, K.; Piekarska, A.; Tronina, O.; Madej, G.; Garlicki, A.; Lucejko, M.; Pisula... Journal: Alimentary pharmacology & therapeutics Issue: Volume 44:Issue 9(2016) Page Start: 946 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Treatment of HCV infection in Poland at the beginning of the interferon‐free era—the EpiTer‐2 study. Issue 6 (6th February 2018) Authors: Flisiak, R.; Zarębska‐Michaluk, D.; Janczewska, E.; Staniaszek, A.; Gietka, A.; Mazur, W.; Tudrujek, M.; Tomasiewicz, K.; Belica‐Wdowik, T.; Baka‐Ćwierz, B.; Dybowska, D.; Halota, W.; Lorenc, B.; Sitko, M.; Garlicki, A.; Berak, H.; Horban, A.; Orłowska, I.; Simon, K.; Socha, Ł. Journal: Journal of viral hepatitis Issue: Volume 25:Issue 6(2018) Page Start: 661 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗